Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

PHASE2CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Peanut Allergy
Interventions
BIOLOGICAL

Viaskin Peanut 250 mcg

Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract

Trial Locations (22)

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

33076

Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Bordeaux

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

54511

Hôpitaux De Brabois, Vandœuvre-lès-Nancy

59020

Hôpital Saint Vincent de Paul, Lille

60611

Children's Memorial Hospital, Chicago

67091

Nouvel Hôpital Civil, Strasbourg

75235

Children's Medical Center Dallas, Dallas

75743

Hôpital Necker, Paris

92123

University of California, Rady Childrens Hospital, San Diego

94305

Stanford University School of Medicine, Stanford

98115

ASTHMA, Inc., Seattle

02114

Massachusetts General Hospital, Boston

02115

Boston Childrens' Hospital, Boston

L5A 3V4

Cheema Research Inc., Mississauga

K1Y 4G2

Ottawa Allergy Asthma Research Institute, Ottawa

M4V 1R2

Gordon Sussman Clinical Research, Toronto

G1V 4M6

Centre de Recherche Appliquée en Asthme et Allergie de Québec, Sainte-Foy

06200

GCS des hôpitaux pédiatriques, Nice

3015 GD

Erasmus MC, Rotterdam

3584 CX

UMC Utrecht, Utrecht

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DBV Technologies

INDUSTRY

NCT01955109 - Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children | Biotech Hunter | Biotech Hunter